Trump gov’t directs visa officers to consider obesity, diabetes in denials: report
Werte in diesem Artikel
WASHINGTON — U.S. Secretary of State Marco Rubio has told overseas diplomatic missions that the United States will consider obesity, diabetes, cancer and other health conditions as grounds to deny visas, a report said Thursday, as President Donald Trump's administration seeks to reduce immigration. Citing a Nov. 6 State Department cable, The Washington Post reported that Rubio told U.S. consulates and embassies about the directive -- a move expected to toughen screening procedures for visa applicants, including South Koreans seeking educational, business and other opportunities in the United States. The directive was issued under the "public charge" rule — a U.S. immigration law under which visas or green cards can be denied if an applicant is expected to become primarily dependent on the U.S. government for subsistence. "You must consider an applicant's health," the cable read, according to the newspaper. "Certain medical conditions — including, but not limited to, cardiovascular diseases, respiratory diseases, cancers, diabetes, metabolic diseases, neurological diseases, and mentWeiter zum vollständigen Artikel bei Korea Times
Übrigens: Visa und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und Neukunden-Bonus sichern!
Ausgewählte Hebelprodukte auf Visa
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Visa
Der Hebel muss zwischen 2 und 20 liegen
| Name | Hebel | KO | Emittent |
|---|
| Name | Hebel | KO | Emittent |
|---|
Quelle: Korea Times
Nachrichten zu Visa Inc.
Analysen zu Visa Inc.
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.10.2025 | Visa Overweight | JP Morgan Chase & Co. | |
| 17.07.2025 | Visa Outperform | RBC Capital Markets | |
| 17.07.2025 | Visa Outperform | Bernstein Research | |
| 30.04.2025 | Visa Buy | UBS AG | |
| 30.04.2025 | Visa Overweight | JP Morgan Chase & Co. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 29.10.2025 | Visa Overweight | JP Morgan Chase & Co. | |
| 17.07.2025 | Visa Outperform | RBC Capital Markets | |
| 17.07.2025 | Visa Outperform | Bernstein Research | |
| 30.04.2025 | Visa Buy | UBS AG | |
| 30.04.2025 | Visa Overweight | JP Morgan Chase & Co. |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 18.05.2018 | Visa Neutral | UBS AG | |
| 15.04.2016 | Visa Neutral | Compass Point | |
| 24.07.2015 | Visa Hold | Topeka Capital Markets | |
| 24.07.2015 | Visa Mkt Perform | FBR Capital | |
| 30.01.2015 | Visa Mkt Perform | FBR Capital |
| Datum | Rating | Analyst | |
|---|---|---|---|
| 01.11.2012 | Visa sell | UBS AG | |
| 12.09.2012 | Visa sell | UBS AG | |
| 26.07.2012 | Visa sell | UBS AG | |
| 09.07.2012 | Visa sell | UBS AG | |
| 11.12.2008 | Visa underperform | Cowen and Company, LLC |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Visa Inc. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen
